Clinical trialPhase 3Terminated
Adjuvant Versus Neoadjuvant Plus Adjuvant Chemotherapy in Resectable Pancreatic Cancer
Adjuvant Gemcitabine Versus NEOadjuvant Gemcitabine/Oxaliplatin Plus Adjuvant Gemcitabine in Resectable PAncreatic Cancer: a Randomized Multicenter Phase III Study (NEOPAC Study)
- Outcome
- Stopped earlylow recruitment (Enrollment)
- Phase
- Phase 3
- Status
- Terminated
- Study type
- Interventional
- Start
- September 2009
- Expected end
- May 2019
- Enrollment
- 38 participants
- Sites
- 5
- Primary outcomes
- Progression-free survival
- Sponsor
- Other
- Results posted
- No
- Last update
- 25 July 2019
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess. Only its metadata is loaded so far, so most questions will be declined.
Try